 CAMBRIDGE, Mass., April 01, 2022 GLOBE NEWSWIRE -- Immuneering Corporation Nasdaq: IMRX, a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today announced that management will participate in Piper Sandlers AIML Investor Conference to discuss software, artificial intelligence and bioinformatics in drug development. Participating will be Ben Zeskind, Ph.D., Co-Founder, President and Chief Executive Officer of Immuneering. Immuneering has more than a decade of experience applying translational bioinformatics to generate insights into drug mechanism of action and patient treatment response. Building on this experience, Immuneerings disease-agnostic discovery platform enables the company to create product candidates based on 1 biological insights that are both counterintuitive and deeply rooted in data, and 2 novel chemistry. 